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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is typically characterized by high chemoresistance
and metastatic spread, features mainly attributable to cancer stem cells (CSCs). It is of central interest the
characterization of CSCs and, in particular, the study of their metabolic features in order to selectively
identify their peculiarities for an efficient therapeutic approach. In this study, CSCs have been obtained
by culturing different PDAC cell lines with a specific growth medium. Cells were characterized for
the typical stem/mesenchymal properties at short-, medium-, and long-term culture. Metabolomics,
proteomics, analysis of oxygen consumption rate in live cells, and the effect of the inhibition of lactate
transporter on cell proliferation have been performed to delineate the metabolism of CSCs. We show
that gradually de-differentiated pancreatic cancer cells progressively increase the expression of both
stem and epithelial-to-mesenchymal transition markers, shift their metabolism from a glycolytic to an
oxidative one, and lastly gain a quiescent state. These quiescent stem cells are characterized by high
chemo-resistance, clonogenic ability, and metastatic potential. Re-differentiation reverts these features,
re-activating their proliferative capacity and glycolytic metabolism, which generally correlates with
high aggressiveness. These observations add an important piece of knowledge to the comprehension
of the biology of CSCs, whose metabolic plasticity could be exploited for the generation of promising
and selective therapeutic approaches for PDAC patients.
Keywords: cancer stem cells; pancreatic ductal adenocarcinoma; cancer metabolism; quiescence;
metabolic plasticity
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1. Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and
is expected to become the second within the next decade [1]. At the time of diagnosis, most patients
have an unresectable tumor and, among patients who undergo surgical resection, more than 85%
with no evidence of metastasis die within 5 years [2,3], consistently with early spread. Although the
understanding of pancreatic cancer biology and genetics has improved, no significant advances in
PDAC treatment have been realized in more than 10 years [4], especially due to high chemotherapy and
radiation resistance [5]. An increasing number of studies are showing that these traits of PDAC are due
to the presence of a small subset of cells with very aggressive features, called cancer stem cells (CSCs),
which are responsible to drive tumorigenesis and to play a fundamental role in disease relapse [6,7].
Interestingly, in a mouse model of PDAC, it has been shown that cellular dissemination leading to
metastasis occurs before the formation of an identifiable primary tumor [8]. This behavior has been
associated with the presence of circulating pancreatic cells that show a mesenchymal phenotype and
express typical stem markers, thus linking CSCs to epithelial-to-mesenchymal transition (EMT) [8].
Indeed, it is widely accepted that CSCs and EMT are strictly interconnected and that activation
of the EMT program is necessary not only for the physical dissemination of tumor cells to distant
tissues, but also for their entrance into the CSC state [9]. Furthermore, in order to proliferate and to
colonize a secondary organ, extravasated mesenchymal cancer cells need to perform the opposite
transformation, i.e., the mesenchymal-to-epithelial transition (MET) [9]. This interchangeability of state
highlights the crucial roles of CSCs in carcinogenesis, metastasis, relapse, and resistance to standard
anti-neoplastic therapies [10,11]. Therefore, the study of CSC features is crucial for their targeting,
which may permanently remove tumor and avoid late relapse [12].
In addition, CSCs possess particular metabolic properties that distinguish them from the bulk of
the tumor. Importantly, the metabolic requirements of cancer cell subpopulations can be exploited for
therapeutic purposes [13], and thus the study of CSC metabolism may open the way for the discovery
of new potential drugs. Consistently, Viale et al. have found that dormant tumor cells with CSC
properties and oxidative metabolism survive Kras ablation in a mouse model of pancreatic cancer and
are responsible for tumor relapse [14]. However, metabolic profiling of CSCs has generally revealed
inconsistent phenotypes and it is not yet clear whether they preferentially rely on a more glycolytic
or oxidative metabolism in comparison to differentiated tumor cells [15,16]. This divergence may be
attributable to the different protocols used to obtain or isolate CSCs. Ideally, their isolation directly
from in vivo tumors appears to be the best approach for their metabolic characterization. However,
this procedure has two main limits: First, the low CSC abundance in the tumor mass renders necessary
their in vitro amplification to get enough material to perform biochemical experiments [17], and second,
the choice of CSC specific surface markers for their sorting from the tumor bulk may lead to the loss of
CSC subtypes that do not express the chosen markers [18]. For these reasons, cancer cell lines remain
an indispensable tool for CSC research [6,19]. Up to now, studies of CSC metabolism have generally
focused on short term culture. We have previously shown that CSCs derived from the PDAC cell line
Panc1 cultured for short periods preferentially rely on glycolysis, fatty acid synthesis, and mevalonate
pathways [20]. The metabolic changes and properties of CSC over longer time periods, which may
more accurately reflect their in vivo state, is unexplored.
In this study, we have progressively de-differentiated PDAC cells and followed their metabolic
needs towards the acquisition of the final stem/mesenchymal state. We have characterized both stem
and metabolic properties of CSCs at three different de-differentiation stages and we demonstrate that,
instead of possessing static metabolic features, gradually de-differentiated CSCs show a metabolic
plasticity that ends with the acquisition of a quiescent state. These dormant cells can re-emerge from
quiescence, re-start to proliferate, and re-activate metabolic requirements for lactate accumulation,
a sign of high aggressiveness. Our findings have important implications for the metabolic targeting
of CSCs for therapy and suggest that metabolic plasticity may represent an obstacle for the use of
metabolic inhibitors.
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2. Materials and Methods
2.1. Drugs and Chemicals
Gemcitabine (Jemta, Sandoz, USA) and Oxaliplatin (Sigma-Aldrich, Germany) were solubilized in
water. Sorafenib, (BAY43-9006, Bayer) and AZD3965 (Cayman Chemical Company) were solubilized
in DMSO. Gemcitabine was stored at −80 ◦C, Oxaliplatin at +4 ◦C, Sorafenib at room temperature
until use, and AZD3965 at −20 ◦C. Vybrant™ Dil cell-labeling solution (Invitrogen, USA) was stored at
+4 ◦C.
2.2. Cell Lines
The pancreatic adenocarcinoma cell lines Panc1, PaCa44, PaCa3, and PC1J were grown in
RPMI-1640 supplemented with 10% FBS and 50µg/mL gentamicin sulfate (all from Gibco/Life
Technologies, USA), here reported as differentiated-cell medium (DM), and were maintained at
37 ◦C with 5% CO2. CSCs were obtained as previously described [6]. Briefly, adherent cells were
washed twice in 1× PBS (Gibco/Life Technologies, USA) and then cultured in stem-specific medium
(SsM), i.e., DMEM/F-12 without glucose (US Biological Life Sciences, USA) supplemented with 1 g/L
glucose, B27, 1 µg/mL fungizone, 1% penicillin/streptomycin (all from Gibco/Life Technologies, USA),
5 µg/mL heparin (Sigma/Merck), 20 ng/mL epidermal growth factor (EGF), and 20 ng/mL fibroblast
growth factor (FGF) (both from PeproTech, United Kingdom). Panc1, PaCa44, PaCa3, and PC1J CSCs
were cultured in flasks with a hydrophobic surface specifically designated for the growth of suspension
cells and were maintained at 37 ◦C with 5% CO2 in the SsM until 8–12 weeks, refreshing twice a week
with new medium. Before each experiment, the cells were passed through a cell stranier (40 µm) to
separate and maintain only the cell aggregates/spheres, which were trypsinized to obtain single cell
suspension. The viability percentage for cell aggregates with a size >40 µm was always higher than
85% (see “Cell proliferation assay” chapter for the method). In particular, the average of the percentage
of viability for Panc1 cell line with a size >40 µm was 94% for parental (P) cells, 93% for CSCs after
2 weeks, 89% for CSCs after 4 weeks, 89% for CSCs after 8 weeks of culture in SsM. Adherent cells
derived from CSCs (AdCSCs) were obtained by completely replacing the SsM, in which CSCs were
growing, with the DM. In these conditions, cells were cultured for more than 2 months. Bright field
cell images were acquired with inverted microscope (Axio Vert. A1, Zeiss, Germany). In all the assays,
both P cells and AdCSCs were cultured in proliferating conditions and not in cell growth arrest due to
contact inhibition.
2.3. RNA Extraction and qPCR
Total RNA was extracted from 1 × 106 cells (Panc1, PaCa44, PaCa3, and PC1J parental cells and
their respective CSCs) using TRIzol Reagent (Life Technologies, USA) and 1 µg of RNA was reverse
transcribed using first-strand cDNA synthesis. Real-time quantification was performed in triplicate
samples by SYBR-Green detection chemistry with GoTaq qPCR Master Mix (Promega, USA) on a
QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, USA). The primers used were: CDH1
forward, 5′-GACACCAACGATAATCCTCCGA-3′ and reverse, 5’-GGCACCTGACCCTTGTACGT-3′;
CyclinB1 forward, 5′-CATGGTGCACTTTCCTCCTT-3′ and reverse, 5′-AGGTAATGTTGTAGAGTT
GGTGTCC-3′; Enolase forward, 5′-TACGTTCACCTCGGTGTCTG-3′ and reverse, 5′-TCTCCCTG
GCATGGATCTT-3′; GLUT1 forward, 5′-CATCATCTTCATCCCGGC-3′ and reverse, 5′-CTCCTCGT
TGCGGTTGAT-3′; MAD2L1 forward, 5′-TTGCTTGTAACTACTGATCTTGAGC-3′ and reverse,
5′-TTCTGAACTGAACACTTGTATAACCA-3′; NANOG forward, 5′-AGTCCCAAAGGCAAACAACC
CACTTC-3′ and reverse, 5′-TGCTGGAGGCTGAGGTATTTCTGTCTC-3′; OCT3/4 forward, 5′-GACAG
GGGGAGGGGAGGAGCTAGG-3′ and reverse, 5′-CTTCCCTCCAACCAGTTGCCCCAAAC-3′; PFK
forward, 5′-TGTGGTTCGAGTTGGTATCTT-3′ and reverse, 5′-GCACTTCCAATCACCGTGCC-3′;
RPLP0 forward, 5′-ACATGTTGCTGGCCAATAAGGT-3′ and reverse, 5′-CCTAAAGCCTGGAAAAA
GGAGG-3′; SOX2 forward, 5′-GGGAAATGGGAGGGGTGCAAAAGAGG-3′ and reverse, 5′-TTGCG
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TGAGTGTGGATGGGATTGGTG-3′; ZEB1 forward, 5′-GTTACCAGGGAGGAGCAGTGAAA-3′ and
reverse, 5′-GACAGCAGTGTCTTGTTGTTGTAGAAA-3′; and housekeeping gene SDHA forward,
5′-GGACCTGGTTGTCTTTGGTC-3′ and reverse, 5′-CCAGCGTTTGGTTTAATTGG-3′ [21].
The cycling conditions used were: 95 ◦C for 10 min, 40 cycles at 95 ◦C for 15 s, 60 ◦C for 1 min,
95 ◦C for 15 s, and 60 ◦C for 15 s. The average of cycle threshold of each triplicate was analyzed
according to the 2-∆∆Ct method. The heatmap, also called clustergram, is a graphic representation
of the unsupervised hierarchical clustering of target gene expression across all samples in the study.
The software, which is the Relative Quantification application of Thermo Fisher Connect, uses Pearson’s
correlation to calculate distances between samples and assays for hierarchical clustering based on their
∆CT values.
2.4. Cell Proliferation Assay
Panc1 parental cells and CSCs at 2, 4, and 8 weeks of culture were plated in 96-well cell culture plates
(5 × 103 cells/well) in their respective medium and were incubated at 37 ◦C with 5% CO2. Viable cells
were counted by Trypan Blue dye exclusion after 2, 4, 7, and 10 days of culture. The doubling time was
calculated using the formula T = (T2−T1) × log2/log (Q2/Q1), where: T1, day 0; T2, day 10; Q1, cell number
at day 0; and Q2, cell number at day 10. To test the cell viability after treatment, cells were seeded in
96-well plates (5 × 103 cells/well) and, the day after, were incubated with compounds at the following
concentrations: 50 nM AZD3965, 100 µM Oxaliplatin, 50 µM Gemcitabine, and 20 µM Sorafenib. At the
end of the treatment (72 h for AZD3965 and 48 h for all other compounds), cell growth was measured by
Resazurin assay (Immunological Sciences, Italy) according to the manufacturer’s protocol and fluorescence
was measured by Tecan GENios Pro Microplate reader (Ex: 535 nm, Em: 590 nm).
2.5. Clonogenic Assay
Briefly, 1 × 106 Panc1 parental cells and CSCs at 2, 4, and 8 weeks of culture were washed with
1X PBS and incubated with CellTrace™ CFSE (1:1000) (Thermo Fisher Scientific, USA) at 37 ◦C for
10 min, protected from light. Cold culture medium was added to block the reaction and the cells were
incubated for 5 min in ice. After 2 washes with 1X PBS, the green cells (Ex: 488 nm, Em: 530/30 nm)
were sorted and 1 cell/well was plated in DM for parental cells and in SsM for CSCs in 96-well cell
culture plates with a FACSAria cell sorter equipped with a 100 µm nozzle (Beckton Dickinson, USA).
At least three 96-well plates for each condition were prepared. The wells in which the cells were more
than 3, indicating the ability of a single cell to duplicate, were counted after 2 weeks. The cells were
photographed by inverted microscope (Axio Vert. A1, Zeiss, Germany) and the diameter of the spheres
was measured after 1 month with ImageJ software (ImageJ, http://rsb.info.nih.gov/ij/, 1997–2008).
2.6. Soft Agar Colony Formation Assay
Panc1 parental cells and CSCs at 2, 4, and 8 weeks of culture were resuspended in 2X RPMI-1640
medium or 2X DMEM/F-12, respectively, containing 0.6% agarose (upper layer). The bottom layer of
solidified matrix was made up of 1% agarose in 2X RPMI-1640 or 2X DMEM/F-12. Cells were plated in
a 6-well plate with a concentration of 5 × 104 cells for each well. All cells were maintained at 37 ◦C
with 5% CO2 for 3 weeks. Colonies were stained with crystal violet and photographed by inverted
microscope. ImageJ software was used to quantify the diameter of colonies, which were considered
formed by more than two cells (diameter ≥25 µm). Instead, a diameter <25 µm is referred to cell debris,
one, or two cells.
2.7. Cell Cycle Analysis
Cell cycle distribution of Panc1 parental cells and CSCs at 2, 4, and 8 weeks of culture was analyzed
using propidium iodide (PI)-stained cells. Briefly, 3 × 105 cells were washed with 1X PBS, incubated
5 min with 0.1% sodium citrate dihydrate, 0.1% Triton X-100, 200 µg/mL RNase A, 50 µg/mL propidium
iodide (Roche Molecular Biochemicals, USA), lysed with a syringe needle, and analyzed using a flow
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cytometer (FACSCanto, Becton Dickinson, USA). The percentage of nuclei in the various stages of the
cell cycle was determined using the ModFit LT software (v. 5.0.9; Verity Software House, Topsham, ME).
2.8. Senescence Analysis
Panc1 parental cells and CSCs at 2, 4, and 8 weeks of culture were plated in 24-well cell culture
plates (3 × 104 cells/well) in their respective medium and were incubated at 37 ◦C with 5% CO2.
After 48 h, when the cells reached a confluence of 70%, the growth media was removed from the cells
and the cells were washed with 1× PBS. The cells were fixed with Fixative Solution at room temperature
for 30 min, washed with 1× PBS, and incubated with β-Galactosidase Staining Solution at 37 ◦C
overnight in dry incubator. The cells were visualized and counted with inverted microscope (Axio Vert.
A1, Zeiss, Germany): Blue color due to β-Galactosidase activity at pH 6 is present only in senescent
cells and not in pre-senescent, quiescent or immortal cells. We used Senescence β-Galactosidase
Staining Kit supplied by Cell Signaling Technology.
2.9. Omic Analyses
For proteomics analyses, the data indicated in this paper are extrapolated from an ongoing
study on the proteomics and lipidomics analysis of CSCs. In particular, the reported proteome
modulations were obtained by a label free approach, as previously described [22]. Briefly, total
proteins from Panc1 parental cells and CSCs grown for 2, 4, and 8 weeks were extracted and
analyzed by LC-MS/MS using the SWATH method and the differentially expressed proteins were
selected according to a statistically significant p-value <0.05 and a fold change threshold of 1.5.
The UNIPROT ID of the identified modulated proteins reported here are the following: Aldolase A
(P04075-2), ATP-dependent citrate lyase (P53396-3), cytochrome c oxidase subunit 2 (P00403), enolase
(P06733), glucose-6-phosphate isomerase (P06744-2), NADH dehydrogenase iron-sulfur protein 3
(O75489), phosphoenolpyruvate-carboxykinase (Q16822), phosphofructokinase (Q01813-2), pyruvate
dehydrogenase E1 component subunit alpha (P08559), pyruvate dehydrogenase E1 component subunit
beta (P11177), succinate dehydrogenase flavoprotein subunit A (P31040), succinate dehydrogenase
iron-sulfur subunit B (P21912), and transketolase (P29401).
For metabolomics analyses, 1x106 cells per group (Panc1 parental cells, CSCs and AdCSCs) were
used. To lyse cells, cell culture pellets were re-suspended in 0.15 mL of ice-cold ultra-pure water
(18MΩ). The tubes were plunged into dry ice (or a circulating bath at −25 ◦C) for 30 s and then into a
water bath at 37 ◦C for 30 s. Six hundred µl of −20 ◦C methanol and then 450 µL of −20 ◦C chloroform
were added to each tube. The contents of the tubes were mixed by gentle rotation every 5 min for
30 min. Subsequently, 0.15 mL of ice-cold pH-adjusted ultra-pure water was added to each tube and
these were centrifuged at 1000× g for 1 min at 4 ◦C, before being transferred to −20 ◦C for 2–8 h.
After thawing, liquid phases were recovered and an equivalent volume of acetonitrile was added to
precipitate any residual protein. The tubes were then transferred to a refrigerator (4 ◦C) for 20 min,
centrifuged at 10,000× g for 10 min at 4 ◦C and the collected supernatants were dried to obtain visible
pellets. Finally, the dried samples were re-suspended in 0.1 mL of water, 5% formic acid and transferred
to glass autosampler vials for LC/MS analysis. Twenty microliters of supernatants (three technical
replicates) were injected into an Ultra High-Performance Liquid Chromatography (UHPLC) system
(Ultimate 3000, Thermo Fisher, USA) and run in positive ion mode. Chromatographic separations
were carried on a Reprosil C18 column (2.0 mm × 150 mm, 2.5 µm, Dr Maisch, Germany), at a column
temperature of 30 ◦C and a flow rate of 0.2 mL/min. A 0–100% linear gradient of solvent A (ddH2O,
0.1% formic acid) to B (acetonitrile, 0.1% formic acid) was employed over 20 min, returning to 100% A in
2 min and a 6 min post-time solvent A hold. The UHPLC system was coupled online with a Q Exactive
(Thermo Fisher, USA) mass spectrometer scanning in full MS mode (2 µscans) at 70,000 resolution in
the 67 to 1000 m/z range, target of 1 × 106 ions and a maximum ion injection time (IT) of 35 milliseconds.
Source ionization parameters were: spray voltage, 3.8 kV; capillary temperature, 300 ◦C; sheath gas,
40; auxiliary gas, 25; S-Lens level, 45. Calibration was performed before each analysis against positive
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ion mode calibration mixes (Piercenet, Thermo Fisher, USA) to ensure sub ppm error of the intact mass.
Raw files of replicates were exported and converted into mzXML format through MassMatrix, then
processed by MAVEN software (http://maven.princeton.edu/). Mass spectrometry chromatograms were
elaborated for peak alignment, matching and comparison of parent and fragment ions, and tentative
metabolite identification (within a 2 ppm mass-deviation range between observed and expected results
against the imported KEGG database). Statistical analyses were performed on the entire metabolomics
data set by using the MetaboAnalyst 4.0 software (http://metpa.metabolomics.ca/). Before the analysis,
raw data were normalized by sum and auto-scaled. False discovery rate (FDR) was used for controlling
multiple testing. Pathway analysis was performed utilizing the MetPA (Metabolomic Pathway
Analysis) web-based tool incorporated into MetaboAnalyst platform. Data for identified metabolites
detected in all samples were submitted into MetPA with annotation based on common chemical
names. Accepted metabolites were verified manually using HMDB, KEGG, and PubChem databases.
The Homo sapiens pathway library was used for pathway analysis. Global test was the selected
pathway enrichment analysis method, whereas the node importance measure for topological analysis
was the relative betweenness centrality.
Controlled experiments of key metabolites, including glucose, glucose-6-phosphate, fructose
1,6-bisphosphate, lactate, fumarate, malate, and phosphogluconolactone, showed a similar regulation
in Panc1 CSCs cultured in SsM with 1 or 2 g/L of glucose compared to Panc1 parental cells, indicating
that the amount of glucose in the medium was not critical for the determination of cell metabolic
features. Beside glucose, it is noteworthy that the two culture media (for details see “Cell lines” section)
do not differ in l-glutamine concentration and that B27 does not contain either glucose or glutamine,
indicating that the medium composition should not influence the metabolic features of the cells.
2.10. Oxygen Consumption Rate (OCR)
Mitochondrial oxygen consumption was assessed with the Seahorse Extracellular Flux Analyzer
XF24 (Seahorse Bioscience, USA) as previously discussed [23]. The XF-24 cell culture plate was coated
with 0.01% poly-l-lysine (P4832, Sigma-Aldrich, Germany) and incubated at room temperature for
at least 1 h and half. Then, the plate was washed once with 1× PBS and dry at room temperature.
Panc1 parental cells and CSC aggregates/spheres, with a size >40 µm, were plated in the treated plate
(6 × 104 cells/well and 1 × 105 cells/well, respectively) in the presence of their respective medium and
were incubated at 37 ◦C with 5% CO2 overnight. Assays were initiated by centrifuging the seahorse
plate for 15 min at 5000× g, replacing the growth medium with 670 µL serum and antibiotic-free
unbuffered DMEM (Ph 7.4) supplemented with 2 mM glutammate and 1 mM pyruvate, and by
incubating the plate at 37 ◦C for 20 min. After the probes were calibrated, the OCR was detected in
basal condition and in presence of the following compounds regulating mitochondrial respiration:
oligomycin (ATP synthase inhibitor; 1 µM), carbonylcyanide p-trifluoro methoxyphenylhydrazone
(FCCP) (uncoupler; 400 nM), rotenone (complex I inhibitor; 1 µM), and antimycin A (complex III
inhibitor; 1 µM). The OCR values were normalized on protein amount. Briefly, after the measurements,
cells were collected, lysed in extraction buffer containing 150 mM NaCl, 20 mM TRIS/HCL pH7.4, 5mM
EDTA, 1% triton, and 10% glycerol and quantified by Bradford Assay.
2.11. Zebrafish
Zebrafish experiments were performed at the Interdepartmental Centre for Experimental Research
(CIRSAL) of the University of Verona. Zebrafish embryos obtained from Nacre adults [24] were
maintained under standard husbandry conditions and mated according to standard procedures.
For xeno-transplantation experiments, zebrafish embryos were dechorionated at 2 days post fertilization
(dpf), anesthetized with tricaine and positioned ventrally in 3% methylcellulose on a plastic mould.
Panc1 parental cells and CSCs at 2, 4, and 8 weeks of culture were washed with 1× PBS and stained
with Vybrant Cell-Labeling Solution for 10 min at 37 ◦C according to manufacturer instructions. Then,
cells were washed with 1× PBS, resuspended in RPMI 1640 without serum and keep on ice until the
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injections. Stained cells were loaded in a glass capillary needle and microinjected into the yolk of
the zebrafish embryos by means of a WPI PicoPump apparatus under a Leica M80 stereomicroscope.
Injected embryos were grown at 33 ◦C and monitored from 1 day post injection (dpi) up to 4 dpi
(experimental endpoint). Images were taken using a Leica MZ16F fluorescence microscope equipped
with a DFC7000T camera. All the analyses on zebrafish larvae have been performed in at least
two independent experiments and a chi-square test was used to determine significance. For each
experimental condition at least 70 larvae have been examined and scored. All experiments were carried
in accordance to Italian law on animal experimentation (D.L. 4 March 2014, n.26).
2.12. Statistical Analysis
ANOVA (post hoc Bonferroni) analysis by GraphPad Prism 5 (GraphPad Software, Inc., USA)
or student’s t-test (two-tailed) were conducted. p-values < 0.05, 0.01, or 0.001 are considered
significantly different.
3. Results
3.1. Long-Term Culture in the Stem-Specific Medium Elicits the Stem and Mesenchymal Properties in
PDAC Cells
Several papers attempted to delineate CSC metabolism reporting contrasting results due to the
different methodological approaches and to the generally short in vitro culture periods, leaving open
the matter on which is the metabolic setting of CSCs. In this paper, we cultured PDAC cells in vitro in
a stem-specific medium (SsM) (see materials and methods) at three different time points, short-term
(2 weeks), medium-term (4 weeks), and long-term (8 weeks). This approach allowed us to study
and follow during the time the phenotypic and metabolic changes of progressively de-differentiated
CSCs, helping to shed light on the stemness acquisition by cancer cells. Noteworthily, our preliminary
data show that when PDAC cells are cultured in the SsM, they quickly change their morphology by
starting to grow in suspension approximately after 24 h (Supplementary Figure S1A). This observation
suggests that our cellular model obtained through the use of the SsM preferentially derives from
de-differentiation of the original parental cells rather than selection of pre-existing stem cells among
the differentiated pull of parental cells. During the de-differentiation process, we observed that all the
four analyzed PDAC cell lines change their morphology (Figure 1A, for Panc1 cells and Supplementary
Figure S1B, for PaCa44, PaCa3, and PC1J cells). Indeed, Figure 1A shows that at 2 weeks, Panc1
cells form random floating aggregates, which decrease in volume at 4 weeks by finally forming big
and round-shaped spheres at 8 weeks of culture, maintaining these features even after 12 weeks
of culture (Supplementary Figure S1C). Together with the acquisition of a spherical morphology,
long-term culture induces more mesenchymal and stem features in comparison to the short- and
medium-term culture. In particular, only after 8 weeks of culture, Panc1 cells show a significantly
decreased expression level of the epithelial marker E-cadherin gene (CDH1), together with an increased
expression of the mesenchymal marker ZEB1, strongly suggesting the loss of the epithelial state and
the acquisition of the mesenchymal phenotype (Figure 1B), in line with the formation of tumorspheres
(Figure 1A). In parallel with these results, three known stem markers are highly expressed in long-term
culture. Indeed, SOX2 mRNA expression is significantly higher after 8 weeks of culture in comparison
to parental cells and to shorter culture periods. Also NANOG and OCT3/4 mRNA expression levels are
significantly increased in long-term culture in comparison to parental cells (Figure 1B). Concerning the
other analyzed PDAC cell lines, they all show a significant increase or a trend of increase of the three
stem markers SOX2, NANOG, and OCT3/4 after 4 and 8 weeks of culture in comparison to parental
cells (Supplementary Table S1).
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Figure 1. Panc1 cells cultured in the stem-specific medium for 2, 4, and 8 weeks enhance their 
epithelial-to-mesenchymal transition (EMT)/stem properties. (A) Bright field representative images 
of Panc1 parental cells (P) and Panc1 cancer stem cells (CSCs) cultured in the stem-specific medium 
for 2, 4, and 8 weeks. Scale bar: 100 μm. (B) qPCR analysis of the basal expression of EMT markers, 
Figure 1. Panc1 cells cultured in the ste -s ifi i for 2, 4, and 8 w eks enhance their
epithelia -to-mes nchymal transition (EMT)/ste . ( ) right field representative images
of Panc1 parental cells (P) and Panc1 cancer stem cel s ( r in the stem-spec fic medium
for 2, 4, and 8 weeks. Scale bar: 10 µm. (B) qP f t e basal expre sion of EMT markers,
i.e., CDH1 and ZEB1, and stem markers, i.e., SOX2, NANOG, and OCT3/4, in Panc1 P cells and CSCs.
The values are reported as fold change relative to P cells. (C) Cell viability analysis of Panc1 P cells and
CSCs treated with 100 µM Oxaliplatin or 50 µM Gemcitabine (GEM) or 20 µM Sorafenib for 48 h.
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(D) Clonogenic assay: The percentage of wells in 96 well-plates with more than 3 cells is reported after
15 days of the seeding of 1 cell/well of Panc1 P cells or CSCs. (E) Soft agar colony formation assay: The
number of Panc1 P or CSC colonies with diameter ≥ 25 µm grown in soft agar is reported after 21 days
of 5 × 104 cells seeded in each well. Histograms legends: white: P cells; light gray: CSCs 2 weeks; dark
grey: CSCs 4 weeks; black: CSCs 8 weeks. (F) Panc1 parental cells and CSCs were stained with Vybrant
Cell Labeling Solution (red) and injected into the yolk of zebrafish larvae at 2 dpf. The percentage of
larvae with metastasis-forming cells was counted at 4 days post injection (dpi) in each experimental
condition and reported in the histograms. Histograms legends: No mets.= larvae with no tumor cells
outside the yolk; n mets < 5 = larvae with <5 tumor cells outside the yolk; n mets > 5 = larvae with
>5 tumor cells outside the yolk. Histograms legends: white: P cells; light gray: CSCs 2 weeks; dark
grey: CSCs 4 weeks; black: CSCs 8 weeks. Values are the means (± SE) of at least three independent
biological replicates for in vitro assays and two biological replicates for in vivo assay. Statistical legend:
p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***) P cells versus CSCs; (§) CSCs 2 weeks versus CSCs 4 weeks;
($) CSCs 2 weeks versus CSCs 8 weeks; (#) CSCs 4 weeks versus CSCs 8 weeks.
Since it has been widely reported that CSCs are strongly chemoresistant thus favoring malignant
progression, metastasis, and cancer recurrence [10], we analyzed the in vitro effects of three different
chemotherapeutic agents on the viability of Panc1 cells. Panc1 cells cultured in SsM were generally
more resistant to Oxaliplatin, Gemcitabine (GEM) or Sorafenib compared to parental cells and the
8-week culture was the most resistant (Figure 1C).
To further investigate the acquisition of the stem features by cells cultured in SsM, we performed
clonogenic assays to evaluate the capability of single cells to undergo clonal expansion, a sensitive
indicator of the undifferentiated state of the cell [25]. We found that Panc1 cells cultured in SsM
possess high clonogenic capability at all the three time points, whereas parental cells do not have this
ability, indicating a more differentiated phenotype (Figure 1D). The diameter of the spheres formed by
cells that were able to give rise to clones (Figure 1D) have been measured 30 days after the plating
(Supplementary Figure S2A,B). Furthermore, it is noteworthy that single cells derived from 8-week
CSCs show the highest clonogenic capability, further supporting a heightened acquisition of stem
features during long-term culture (Figure 1D). Another hallmark of CSCs is represented by their
capability to grow independently of a solid surface. To assess this property on the SsM cultured cells,
we performed the soft agar colony assay, a well-established in vitro method that permits to analyze
anchorage-independent growth based on the colony formation capability of the cells cultured on
the agarose matrix [26]. Cells cultured in SsM increased their colony formation capability with the
highest extent in cells originated from 8-week CSCs (Figure 1E and Supplementary Figure S2C), further
confirming that long-term culture confers stem properties.
Finally, in order to definitively ascertain the acquisition of stem features by the cells, their behavior
in vivo was assayed. In our previous article, we have shown that PDAC CSCs cultured in SsM for
about two weeks possess higher tumor-seeding ability in mice in comparison to parental cells [6].
Since it is known that cells harboring stem and mesenchymal features possess a higher migratory
ability [27], here we aimed to evaluate the metastatic capacity of the obtained cells by injecting Panc1
cells previously cultured at the three time points in SsM and the relative parental cells in zebrafish
(Danio rerio), an animal model that has recently contributed to major insights in the development
and progression of PDAC [28,29]. Indeed, Teng et al. previously reported that different tumor cell
types, including pancreatic cancer cells, injected in zebrafish larvae show a degree of cell metastasis
in fish that is proportional to their invasion potential in vitro [30]. We injected tumor cells into 48 h
post fertilization (hpf) transparent embryos and evaluated the spread of cells 4 days later, a period
which allows cancer cells to survive and metastatize since zebrafish larvae have not yet developed
an adaptive immune system [30]. The data obtained show that, in the 74% of the larvae, the injected
parental cells were confined in the site of injection (yolk), while in 24% of the sample a migration of
tumor cells was observed (Figure 1F). Conversely, cells previously cultured in vitro in the SsM show a
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progressive ability to migrate and give rise to metastasis in an increasing number of larvae (Figure 1F).
The highest number of metastasis-forming cells (79%) was observed in the larvae injected with the cells
previously cultured in SsM for 8 weeks indicating that a direct correlation between the spreading ability
of the cells and the SsM incubation time can be assumed. These in vivo data additionally confirm that
cells cultured in SsM for long periods further increase their aggressiveness and metastatic potential,
which are known features of tumor cells with stem properties [31], and that these characteristics are
maintained also after their injection in vivo, represented here by Zebrafish.
Altogether, these data indicate that cells cultured in SsM at all the three time points possess
stem features. Therefore, we have considered all of them as “cancer stem cells” (CSCs), even though
long-term culture cells show the highest grade of stemness.
3.2. Long-Term Cultured CSCs Enter a Quiescent State
We and others have previously shown that CSCs proliferate slower than differentiated cells [6,32].
Here, we find that cells cultured in SsM lose their proliferative capacity over time, with long-term
cultured cells having the lowest proliferation rate (Figure 2A). Indeed, 8-week CSCs show a 3.6- or
2-fold higher doubling time than parental cells or 2–4-week CSCs, respectively (Table 1, first column),
indicating their entrance in a slow-cycling state. In accordance, the cell cycle distribution analysis shows
that all CSCs have a significant S phase drop in comparison to parental cells and only 8-week CSCs had
a significant accumulation in the G0/G1 phase (Figure 2B and C). In line with our data, other authors
showed that quiescent cells have a doubling time that is about 4 fold higher than the corresponding
proliferating cells [33]. However, we aimed to clarify whether the slow-cycling properties of CSCs
are due to quiescence or senescence. Generally, quiescence is a reversible dormant-state [34], whereas
senescence is a permanent state of cell cycle arrest that takes place due to aging and represents a
degenerative process [35]. In order to exclude senescence, we performed the beta-galactosidase
senescent assay that shows, in all conditions, only a minimal amount of senescent cells (less than
3%) (Supplementary Figure S2D). Hence, to demonstrate that low proliferation rate and G0/G1 phase
accumulation of 8-week CSCs is due to quiescence, we analyzed the expression levels of three proteins
previously shown to be decreased in quiescent cells: The mitotic spindle assembly checkpoint protein
MAD2L1, the cell cycle regulator cyclin B1 [36,37], and a ribonucleoprotein (RPLP0), that belongs to a
family involved in translation [38,39]. Figure 2D shows that: (i) 8-week CSCs had significantly lower
expression levels of MAD2L1 and cyclin B1 in comparison to parental cells and to 4-week CSCs, and (ii)
RPLP0 had a progressively decreased trend of expression during de-differentiation. Also medium- and
long-term cultured CSCs derived from PaCa44, PaCa3, and PC1J cells showed a significant decrease or
a trend of decrease of MAD2L1, cyclin B1 and RPLP0 expression, further supporting the observation
that stem induction by SsM culture is cell line-independent (Supplementary Table S1). Altogether,
these data indicate that the induction of the mesenchymal/stem state of long-term cultures in SsM
affects cell proliferation, cell cycle distribution, and favors the entrance in a quiescence state, which is
considered another typical stem marker [40].
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Figure 2. Long-term culture of cancer stem cells (CSCs) favors the entrance in a quiescent state. (A) 
Proliferation rate of Panc1 P and CSCs cultured in their specific-medium for 2, 4, 7, and 10 days. 5 × 
103 cells/well have been plated for each condition at time 0. Legend: White squared: P cells; gray 
rhombus: CSCs 2 weeks; black triangle: CSCs 4 weeks; star: CSCs 8 weeks. (B) Representative 
histograms of cell cycle analysis for each condition. (C) Cell cycle distribution of Panc1 P cells and 
CSCs through flow cytometry. (D) qPCR analysis of the quiescent markers MAD2L1, Cyclin B1, and 
RPLP0 in Panc1 P cells and CSCs. The values are reported as fold change relative to P cells. 
Histograms legends: white: P cells; light gray: CSCs 2 weeks; dark grey: CSCs 4 weeks; black: CSCs 8 
weeks. Values are the means (± SE) of at least three independent biological replicates. Statistical 
legend: p < 0.05 (*) P cells versus CSCs; ($) CSCs 2 weeks versus CSCs 8 weeks; (#) CSCs 4 weeks 
versus CSCs 8 weeks. 
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(A) Proliferati r te of Panc1 P and SCs c ltured in their specific- edium for 2, 4, 7, and 10 days.
5 × 103 cells/ ell have been plated for each condition at time 0. Legend: White squared: P cells;
gray rhombus: CSCs 2 weeks; black triangle: CSCs 4 weeks; star: CSCs 8 weeks. (B) Representative
histograms of cell cycle analysis for each condition. (C) Cell cycle distribution of Panc1 P cells and CSCs
through flow cytometry. (D) qPCR analysis of the quiescent markers MAD2L1, Cyclin B1, and RPLP0 in
Panc1 P cells and CSCs. The values are reported as fold change relative to P cells. Histograms legends:
white: P cells; light gray: CSCs 2 weeks; dark grey: CSCs 4 weeks; black: CSCs 8 weeks. Values are the
means (± SE) of at least three independent biological replicates. Statistical legend: p < 0.05 (*) P cells
versus CSCs; ($) CSCs 2 weeks versus CSCs 8 weeks; (#) CSCs 4 weeks versus CSCs 8 weeks.
3.3. CSCs Cultured in the Differentiated-Cell Medium Re-Acquire Epithelial Features and Exit from the
Quiescent State
Since quiescence is a reversible phase from which cells may re-enter the cell cycle in response to
physiological cell stimuli, we re-cultured CSCs in the differentiated-cell medium (DM) (see materials
and methods). Figure 3A shows that, after 24 h of culture in DM, cells drastically changed their
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morphology by forming a monolayer adherent to the plate and decreased the expression level of
SOX2 mRNA (data not shown). Furthermore, prolonged culture in DM for 10 days (Figure 3B) or for
more than 2 months (Figure 3C) stimulates cells to accelerate their proliferation rate in comparison to
their previous stem status, as shown by the decreased doubling time (Table 1 s and third columns).
In particular, after 10 days of culture in DM, adherent cells derived from 2- and 4-week CSCs have a
doubling time of less than 3 days and they maintain this doubling time even after more than 2 months
of culture in DM. In contrast, adherent cells derived from 8-week CSCs take a longer time, more than
2 months, to reach the same doubling time than the other cells (Table 1), in line with the prominent
quiescent features of the CSCs of origin. Furthermore, in comparison to their previous stem state,
adherent cells derived from 8-week CSCs and cultured in DM for more than 2 months progressively lost
their mesenchymal features, as shown by the increased expression of the E-cadherin gene and by the
decreased expression of ZEB-1, and show a decreased expression of the stem markers SOX2, NANOG
and OCT3/4 (Figure 3D and Table 2). Finally, the adherent cells derived by all the CSCs express levels of
the quiescent markers similar to those of parental cells (Figure 3E and Table 2). A further confirmation
of the gene expression pattern differences among the stem cells and the derived-adherent cells is
appreciable also in the Heatmap representation of the unsupervised hierarchical clustering of target
gene expression across all samples (Supplementary Figure S3). Altogether, these data further support
the strongest stem features of the long-term cultured CSCs, which need longer time to undergo the
mesenchymal-to-epithelial transition (MET) in comparison to short- and medium-term cultured CSCs.
Table 1. Analysis of doubling time reported as day.
- Doubling Time (Day)
- Standard culture conditions
Adherent cells derived
from CSCs cultured in
DM for 10 days
Adherent cells derived
from CSCs cultured in
DM for ≥ 2 months
P cells 2 ± 0.25 / /
CSCs 2 wk 3.6 ± 0.05 * 2.9 ± 0.31 *,£ 2.9 ± 0.04 *,£
CSCs 4 wk 3.5 ± 0.02 * 2.8 ± 0.34 *,£ 2.6 ± 0.09 *,£
CSCs 8 wk 7.2 ± 0.25 *$,# 3.5 ± 0.46 *,£ 2.6 ± 0.10 *,£,&
Doubling Time (Day)
Standard culture conditions
Adherent cells derived
from CSCs cultured in
DM for 10 days
Adherent cells derived
from CSCs cultured in
DM for ≥ 2 months
P cells 2 ± 0.25 / /
CSCs 2 wk 3.6 ± 0.05 * 2.9 ± 0.31 *,£ 2.9 ± 0.04 *,£
CSCs 4 wk 3.5 ± 0.02 * 2.8 ± 0.34 *,£ 2.6 ± 0.09 *,£
CSCs 8 wk 7.2 ± 0.25 *$,# 3.5 ± 0.46 0,*£ 2.6 ± 0.10 *,£,&
Doubling Time (Day)
Standard culture conditions
Adherent cells derived
from CSCs cultured in
DM for 10 days
Adherent cells derived
from CSCs cultured in
DM for ≥ 2 months
P cells 2 ± 0.25 / /
CSCs 2 wk 3.6 ± 0.05 * 2.9 ± 0.31 *,£ 2.9 ± 0.04 *,£
CSCs 4 wk 3.5 ± 0.02 * 2.8 ± 0.34 *,£ 2.6 ± 0.09 *,£
CSCs 8 wk 7.2 ± 0.25 *,$,# 3.5 ± 0.46 *,£ 2.6 ± 0.10 *,£,&
Viable cells were counted by Trypan Blue dye exclusion after 1, 4, 7, and 10 days. The doubling time was calculated
using the formula T = (T2 - T1) × log 2/log (Q2/Q1), where: T1, day 0; T2, day 10; Q1, cell number at day 0; and Q2,
cell number at day 10. In the first column, the doubling time is referred to cells grown in their standard culture
conditions as reported in materials and method, i.e., differentiated-cell medium (DM) for P cells and stem-specific
medium (SsM) for CSCs. In the second and third column, CSCs where grown in DM for maximum 10 days or at least
2 months, respectively. Values are the means ± SEM of four independent experiments. Statistical legend: p < 0.05 (*)
CSCs or adherent cells derived from CSCs versus P cells; ($) CSCs 2 weeks versus CSCs 8 weeks; (#) CSCs 4 weeks
versus CSCs 8 weeks; (£) adherent cells derived from CSCs versus the relative CSCs; (&) adherent cells derived from
CSCs cultured in DM for 10 days versus the same cells cultured for more than 2 months.
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the quiescent state. (A) Bright field images of adherent cells derived from Panc1 CSCs after 24 h of 
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Figure 3. CSCs cultured in the differentiated-cell medium re-acquire epithelial features and exit from
the quiescent state. (A) Bright field images of adherent cells derived from Panc1 CSCs after 24 h
of culture in the differentiated-cell medium (DM). Scale bar: 100 µm. Proliferation rate of Panc1 P
and adh rent cells der v fro Panc1 CSCs fter 10 days (B) and 2 months (C) of culture in DM.
5 × 103 cells/well have been plated for each condition at ti e 0. Legend: White squared: P cells; gray
rhombus: adherent cells derived from CSCs 2 weeks; black triangle: adherent cells derived from CSCs
4 weeks; star: adherent cells derived from CSCs 8 weeks. Statistical legend: p < 0.05 (a) P cells versus
AdCSCs 2 weeks; (b) P cells versus AdCSCs 4 weeks; (c) P cells versus AdCSCs 8 weeks; (d) AdCSCs 2
weeks versus AdCSCs 4 weeks; (e) AdCSCs 2 weeks versus AdCSCs 8 weeks; (f ) AdCSCs 4 weeks
versus AdCSCs 8 weeks. (D) qPCR analysis of the basal expression of EMT markers, i.e., CDH1 and
ZEB1, and stem markers, i.e., SOX2, NANOG, and OCT3/4, in Panc1 P cells and adherent cells derived
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from Panc1 CSCs after 10 days and 2 months of culture in DM. The values are reported as fold change
relative to P cells. (E) qPCR analysis of the quiescent markers MAD2L1 and Cyclin B1 in Panc1 P cells
and adherent cells derived from Panc1 CSCs after 10 days and 2 months of culture in DM. The values
are reported as fold change relative to P cells. Legend: parental cells: AdCSCs: adherent cells derived
from the indicated CSCs cultured in DM for 10 days or more than 2 months. Values are the means
(± SE) of at least three independent biological replicates. Statistical legend: p < 0.05 (*) P cells versus
AdCSCs; (#) AdCSCs 4 weeks versus AdCSCs 8 weeks; (&) AdCSCs cultured in DM for 10 days versus
the same cells cultured in DM for more than 2 months.
Table 2. mRNA expression levels of stem, EMT, and quiescent markers in parental (P), cancer stem cells
(CSCs), and adherent cells derived from CSCs (AdCSCs) and cultured in the differentiation medium for
10 days or more than 2 months. The data are shown as the average of fold change relatively to P cells ±
standard error.
CDH1
(fold
change)
ZEB1
(fold
change)
SOX2
(fold
change)
NANOG
(fold
change)
OCT3/4
(fold
change)
MAD2L1
(fold
change)
cyclinB1
(fold
change)
P 1 1 1 1 1 1 1
CSCs 2wk 2.32 ± 1.05 1.19 ± 0.28 4.64 ± 0.82 2.67 ± 0.04 2.20 ± 0.10 0.65 ± 0.33 0.31 ± 0.08
CSCs 4wk 1.65 ± 0.54 1.30 ± 0.58 11.85± 3.23 3.54 ± 1.50 2.28 ± 0.69 0.61 ± 0.12 0.69 ± 0.14
CSCs 8wk 0.17 ± 0.01 1.64 ± 0.02 24.42± 6.84 6.99 ± 2.71 3.12 ± 0.70 0.16 ± 0.02 0.14 ± 0.07
AdCSC 2w
10 days 1.12 ± 0.15 0.59± 0.09 0.42 ± 0.11 0.98 ± 0.11 1.70 ± 0.28 0.66 ± 0.11 1.01 ± 0.16
AdCSC 4w
10 days 1.56 ± 0.15 0.98 ± 0.03 0.56 ± 0.15 1.73± 0.46 2.01 ± 0.30 1.11 ± 0.32 0.94 ± 0.12
AdCSC 8w 10 days 1.29 ± 0.27 1.08 ± 0.04 0.30 ± 0.09 0.99 ± 0.18 1.83 ± 0.11 0.83 ± 0.13 0.61 ± 0.11
AdCSC 2w
≥2 months 1.92 ± 0.34 0.67 ± 0.12 0.14 ± 0.05 0.82 ± 0.14 1.53 ± 0.24 0.54 ± 0.06 0.94 ± 0.16
AdCSC 4w
≥2 months 2.75 ± 0.21 0.83 ± 0.11 0.50 ± 0.16 0.80 ± 0.32 2.23 ± 0.15 0.82 ± 0.16 0.86 ± 0.16
AdCSC 8w
≥2 months 2.73± 0.19 0.65 ± 0.06 0.64 ± 0.10 0.57 ± 0.19 1.35 ± 0.15 0.95 ± 0.17 1.07 ± 0.27
3.4. CSCs Modify Their Metabolic Settings Towards the Acquisition of Quiescence Properties
In order to determine whether CSC plasticity, which causes cells to progressively increase their
stem and mesenchymal features finally gaining the quiescent state, is associated with metabolic
changes, we performed an integrative analysis of Panc1 cell and CSC metabolic features by using qPCR,
metabolomics, proteomics, and Seahorse technology. At a first glance, MetaboAnalyst software analysis
of the metabolomics data highlights that CSCs possess stage-specific metabolic phenotypes during
the progressive de-differentiated stages (Supplementary Figure S4, for details see figure legend) and
identifies several pathways as being significantly impacted by the transition to quiescence. We focused
on the main energy metabolism-related pathways, including glycolysis, pentose phosphate pathway,
tricarboxylic acid cycle, electron transport chain, and oxygen consumption. Below, we describe the
data obtained with the different techniques separated for the different time points.
3.5. CSCs Demonstrate an Upregulation of Glycolysis and the PPP, and Downregulation of Oxidative
Phosphorylation, at 2 Weeks of Culture
While we found that the mRNA expression of the glucose transporter Glut1 (Supplementary
Figure S5) and the glycolytic intermediate glucose-6-phosphate (Figure 4A) was increased similarly
in all CSCs in comparison to parental cells, 2-week CSCs demonstrated an increase in the glycolytic
intermediate glyceraldehyde-3-phosphate compared to other time points (Figure 4A). Two-week
CSCs have the highest trend to increase the pentose phosphate pathway (PPP) intermediates
glucono-1,5-lactone-6-phosphate, xylulose-5-phosphate, and sedoheptulose-7-phosphate in comparison
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to parental cells, 4- and 8-week CSCs (Figure 4B). In accordance with the previously described higher level
of glyceraldehyde-3-phosphate in 2-week CSCs (Figure 4A), the expression of the enzyme transketolase,
which drives the formation of glyceraldehyde-3-phosphate and sedoheptulose-7-phosphate in PPP,
is 2.5-fold higher in short-term cultured CSCs, compared to parental cells. Importantly, oxidative
phosphorylation is downregulated (Figure 5A), particularly ATP-linked respiration, suggesting a higher
reliance on glycolytic metabolism to supply cellular ATP. Altogether these data indicate that, at the
beginning of the de-differentiation process, CSCs show increased metabolites in the PPP and glycolysis
pathway, and downregulation of oxidative phosphorylation.
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Figure 4. Progressively CSC de-differentiation is accompanied by metabolic changes. Metabolomic 
quantification of intracellular levels of metabolites reported as fold change relative to parental cells. 
Metabolites from glycolysis (A), pentose phosphate pathway (B), and tricarboxylic acid cycle (C) in 
Panc1 P cells and CSCs cultured for 2, 4, and 8 weeks. Legend: white: parental (P) cells; light gray: 
CSCs 2 weeks; dark grey: CSCs 4 weeks; black: CSCs 8 weeks. Values are the means (± SE) of three 
technical replicates and three independent biological replicates. Statistical legend: p <0.05 (*) P cells 
versus CSCs; (§) CSCs 2 weeks versus CSCs 4 weeks; ($) CSCs 2 weeks versus CSCs 8 weeks; (#) CSCs 
4 weeks versus CSCs 8 weeks. 
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quantification of n racellul r evels of metabolite ported as fold change relative to parental cells.
Metabolites from glycolysis (A), pentose phosphate pathway (B), and tricarboxylic acid cycle (C) in
Panc1 P cells and CSCs cultured for 2, 4, and 8 weeks. Legend: white: parental (P) cells; light gray:
CSCs 2 weeks; dark grey: CSCs 4 weeks; black: CSCs 8 weeks. Values are the means (± SE) of three
technical replicates and three independent biological replicates. Statistical legend: p <0.05 (*) P cells
versus CSCs; (§) CSCs 2 weeks versus CSCs 4 weeks; ($) CSCs 2 weeks versus CSCs 8 weeks; (#) CSCs
4 weeks versus CSCs 8 weeks.
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Figure 5. Metabolic features of CSCs. (A) Seahorse analysis of Panc1 P and CSCs cultured in their 
specific-medium; 6 × 104 cells/well and 1 × 105 cells/well of P and CSCs respectively have been plated 
for each condition. After 24 h, cells were treated with FCCP (400 nM), oligomycin (1 μg), and a mix of 
antimycin and rotenone (both 1 μM) and then analyzed. Histograms legends: white: parental (P) cells; 
light gray: CSCs 2 weeks; dark grey: CSCs 4 weeks; black: CSCs 8 weeks. (B) Cell viability analysis of 
Panc1 P cells and CSCs treated with 50 nM AZD3965, the MCT-1 inhibitor, for 72 h. Molecular (C) 
Figure 5. Metabolic features of CS s. (A) Seahorse analysis of Panc1 P and CSCs cultured in their
specific-medium; 6 × 104 cells/well and 1 × 105 cells/well of P and CSCs respectively have been plated
for each condition. After 24 h, cells were treated with FCCP (400 nM), oligomycin (1 µg), and a mix of
antimycin and rotenone (both 1 µM) and then analyzed. Histograms legends: white: parental (P) cells;
light gray: CSCs 2 weeks; dark grey: CSCs 4 weeks; black: CSCs 8 weeks. (B) Cell viability analysis of
Panc1 P cells and CSCs treated with 50 nM AZD3965, the MCT-1 inhibitor, for 72 h. Molecular (C) and
schematic (D) representations of the data presented in this paper showing the metabolic plasticity of
CSCs. In green are indicated the metabolites or metabolic enzymes whose intracellular level or expression,
respectively, is decreased. Instead, are reported in red when their level is increased. In italic are reported
the enzyme’s name. Values are the means (± SE) of three independent biological replicates. Statistical
legend: p <0.05 (*) P cells versus CSCs; (§) CSCs 2 weeks versus CSCs 4 weeks; ($) CSCs 2 weeks versus
CSCs 8 weeks; (#) CSCs 4 weeks versus CSCs 8 weeks. Legends: glucose transporter (Glut1); glucose-6
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-phosphate (G6P); fructose-6-phosphate (F6P); fosfofructokinase (PFK); fructose 1,6-bisphosphate
(F1,6bisP); glyceraldehyde-3-phosphate (G3P); dihydroxyacetone phosphate (DAHP); 1,3-bisphospho
glycerate (1,3bisPG); 3-phosphoglycerate (3PG); 2-phosphoglycerate (2PG); phosphoenolpyruvate
(PEP); pyruvate (PYR); monocarboxylate transporter-1 (MCT1); pyruvate dehydrogenase (PDH);
oxaloacetate (OAA); phosphoenolpyruvate carboxykinase (PEPCK); tricarboxylic acid (TCA) cycle;
oxidative phosphorylation (OxPhos); pentose phosphate pathway (PPP).
3.6. CSCs Demonstrate an Upregulation of Oxidative Phosphorylation at 4 Weeks of Culture
We found that keeping CSCs in culture for two more weeks (4-week CSCs) led to the accumulation
of the down-stream glycolytic intermediates 2-phosphoglycerate and phosphoenolpyruvate (Figure 4A).
In contrast, almost all the metabolites of PPP, with the exception of 6-phospho-gluconate, show a
decreased level in 4-week CSCs compared to 2-week CSCs, suggesting a reduction of PPP during the
progression of cell de-differentiation. The parallel proteomic analyses highlight that, in comparison to
2-week CSCs, 4-weeks CSCs express significant lower levels of glucose-6-phosphate isomerase (0.35 fold),
aldolase A (0.57 fold), and enolase (0.62 fold), with no change in the mRNA expression of enolase
(Supplementary Figure 5), suggesting a post-translational regulatory mechanism. Phosphoenolpyruvate
(PEP) accumulation may instead be induced by PEP-carboxykinase, which converts oxaloacetate into
PEP. PEP-carboxykinase protein levels were 5.7- and 2.7-fold higher than parental cells and 2-week
CSCs, respectively. Proteomics analysis also revealed that 4-week CSCs have 1.9-fold higher levels
of both alpha and beta subunits of the PDH component E1 (PDH-E1), the enzyme that irreversibly
converting pyruvate into acetyl-CoA to support a preferred entrance of acetyl-CoA into the TCA cycle
in medium-term cultured CSCs. 4-week CSCs also had high intracellular levels of the TCA cycle
metabolite citrate (Figure 4C), and proteomic data showing that the expression levels of the enzyme
ATP-dependent citrate lyase is 5.2- and, in particular, 8-fold higher in 2- and 4-week CSCs, respectively,
in comparison to parental cells. Citrate lyase catalyzes the cytosolic conversion of citrate into acetyl-CoA,
which can be used by the cells for fatty acid synthesis or histone acetylation [41,42], and oxaloacetate,
which can be converted into PEP by PEP-carboxykinase, shown above to possess the highest expression
level in 4-week CSCs. Other TCA cycle intermediates, such as 2-oxoglutarate, fumarate, and malate,
were decreased in all CSCs in comparison to parental cells (Figure 4C).
Interestingly, proteomic analysis revealed that NADH dehydrogenase (complex I), succinate
dehydrogenase (complex II), and cytochrome C oxidase (complex IV) were highly expressed in 4-week
CSCs in comparison to parental cells and to CSCs cultured for shorter and longer periods. Indeed,
in 4-week CSCs, NADH dehydrogenase is 3 and 2 fold higher than in parental cells and 8-week CSCs,
respectively; succinate dehydrogenase subunit A (SDHA) is 7.3, 2.2, and 3.5 fold higher than in parental
cells, 2- and 8-week CSCs, respectively; succinate dehydrogenase subunit B (SDHB) is 4.3, 1.9, and
2.4 fold higher than in parental cells, 2- and 8-week CSCs, respectively; and cytochrome C oxidase is
1.9 and 1.7 fold higher than parental cells and 2-week CSCs, respectively. Consistently, 4-week CSCs
show the highest oxygen consumption rate (OCR) in Seahorse assay, particularly cellular respiration
coupled with ATP production, suggesting reliance on oxidative phosphorylation (Figure 5A).
3.7. Week-Quiescent CSCs Downregulate Metabolic Processes
Finally, according to the higher doubling time and stem/mesenchymal features, CSCs cultured
for longer periods (8-week CSCs) show decreased trends of the metabolites 2-phosphoglycerate,
phosphoenolpyruvate, and lactate (Figure 4A) and enolase mRNA (Supplementary Figure S5) in
comparison to the previous de-differentiation step (4 weeks of culture). In addition, all analyzed PPP
metabolites were significantly decreased in 8-week CSCs, suggesting a slowdown of this pathway
in quiescent cells. Furthermore, 8-weeks CSCs express significant lower levels of both PFK and
PEP-carboxykinase protein (0.6- and 0.5-fold, respectively) compared to 4-week CSCs. Finally, 8-week
CSCs had the lowest OCR of any time point, with ATP-linked respiration practically undetectable
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(Figure 5A). Together, these data indicate that long-term cultured CSCs diminish their metabolic
requirements together with the deceleration of their proliferation.
Altogether these data demonstrate that, during progressive de-differentiation, CSCs shift from a
more glycolytic to a more oxidative metabolism, accomplishing at 8 weeks of culture a global reduced
metabolism together with the acquisition of a quiescent status. All the described metabolic changes in
CSCs cultured in SsM at the different time points are schematically represented in Figure 5C.
3.8. Metabolic Phenotypes Confer Targetable
Because short-term cultured CSCs had higher glycolytic activity compared to other time points,
we tested whether they would be sensitive to pharmacological inhibition of glycolytic flux. We used
AZD3965, a specific inhibitor of the lactate transporter MCT-1 that is in phase I clinical trial [43].
Inhibition of MCT-1 impairs both the export and the import of lactate, causing pH alteration [44] and
enhances the cytosolic levels of Ca2+ leading to apoptosis [45]. Short-term cultured 2-week CSCs
showed the highest sensitivity to the AZD3965 (Figure 5B). These findings suggest that while both
2-week CSCs and 4-week CSCs have alterations of specific glycolytic intermediates, 4-week CSCs are
less reliant on glycolysis due to upregulation of oxidative phosphorylation. Importantly, metabolic
inhibitors are likely to target CSCs differently depending on their metabolic phenotypes.
3.9. Adherent Cells Derived from CSCs Escape the Quiescent State and Become Metabolically Active
Finally, we analyzed the metabolic settings of adherent cells derived by CSCs that, as described
above, re-acquire epithelial characteristics. The results of these analyses show that adherent cells derived
from all the CSCs cultured for more than 2 months in DM undergo evident changes in glycolysis and PPP
in comparison to their previous stem state (Figure 6A and B), especially regarding phosphoenolpyruvate,
lactate, glucono-1,5-lactone-6-phosphate, and xylulose-5-phosphate. Furthermore, almost all the
glycolytic metabolic intermediates, including glyceraldehyde-3-phosphate, 2-phospho-glycerate,
and phosphoenolpyruvate, and PPP intermediates, including glucono-1,5-lactone-6-phosphate,
6-phospho-gluconate, and xylulose-5-phosphate, show very similar levels among all the adherent
cells derived by CSCs (Figure 6A and B). Concerning TCA intermediates, in comparison to the
CSCs of origin (Figure 4C), the levels of fumarate and malate remain unaltered, whereas the levels
of citrate and, especially, of 2-oxoglutarate drastically change (Figure 6C). Altogether these data
suggest that, when CSCs at the three de-differentiation steps are driven to re-differentiate, they acquire
similar metabolic properties, also in accordance with their comparable proliferation rate reported in
Table 1 (third column), by restoring similar metabolic parameters. In comparison to parental cells,
two late glycolytic intermediates, i.e., phosphoenolpyruvate and lactate, and two PPP intermediates,
i.e., glucono-1,5-lactone-6-phosphate and xylulose-6-phosphate, are strongly accumulated in all
adherent cells derived from CSCs, suggesting a preferential commitment of these cells on glycolysis
and PPP. Interestingly, the average of lactate accumulation for all the adherent cells derived from
CSCs in comparison to parental cells is about 50 fold, suggesting a stronger aggressive feature of
these re-differentiated cells. All these findings indicate that re-differentiated CSCs re-acquire epithelial
morphology and proliferative properties similar to those of parental cells, however still maintaining
some substantial differences that support their stronger malignancy.
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4. Discussion
Pancreatic ductal adenocarcinoma (PDAC) cancer stem cells (CSCs) are a small subpopulation of
cells within the tumor, representing about 0.1–1% of the total mass [31], whose role in tumorigenesis,
metastasis formations, and relapse has been widely demonstrated [46]. Thus, to potentiate the effect
of present therapies, the investigation of CSC features is crucial to identify specific targets. Up to
now, many attempts have been made to characterize the metabolic status of CSCs with contrasting
results. Here, we show for the first time that prolonged culture of PDAC cell lines in a stem-specific
medium progressively lead to the enhancement of cell mesenchymal/stem properties associated with
CSC metabolic plasticity, during which cells switch from a glycolytic to an oxidative metabolism to
finally gain a quiescent state with a global metabolic shut-down. While proliferating cells devote much
of their metabolic capacity to biosynthesis in order to synthesize the material necessary to form a new
cell, quiescent cells are relieved of important metabolic requirements [47]. Consistently, we find that
PDAC cells first shift their metabolic arrangement to a glycolytic metabolism while acquiring CSC
properties (Figure 5D), which may help them to continue to proliferate in the new growth conditions.
This is reflected also by the enhancement of pentose phosphate pathway, necessary for nucleotide
and lipid syntheses, and by the high lactate production, required for the re-oxidation of NADH,
which is indispensable for glycolysis to proceed. Then, during progressive de-differentiation in the
same growth conditions, cells increase their oxidative metabolism by favoring pyruvate entrance into
the TCA cycle and by raising the levels of intracellular citrate and citrate lyase expression, suggesting a
tight epigenetic regulation [41], which could explain such quick transitions and metabolic changes.
Furthermore, the implementation of the oxidative metabolism is also confirmed by the increased oxygen
consumption rate coupled with ATP production. Finally, when the acquisition of stem features is
consolidated, CSCs slowdown their global energy metabolism by entering in a slow-cycling/quiescence
state. This situation is likely to occur in in vivo stem niches where a sub-population of tumor cells
has the capacity to enter a non-dividing state in response, for instance, to lack of nutrients from blood
supply, detachment from the substratum, or hypoxia [48]. The quiescent nature of CSCs represents an
inherent mechanism that may partially explain chemotherapy resistance and recurrence in post-therapy
cancer patients. In fact, during dormancy, cancer cells become clinically undetectable and resistant to
cytotoxic drugs, and their reemergence from dormancy may determine higher aggressiveness [47].
This dormant state is likely to pose a challenge for the metabolic targeting of CSCs, as we find that they
have low metabolic requirements, very low oxidative metabolism, and are concomitantly resistant to
MCT1 inhibition.
Accumulating evidence indicates that conventional therapies often fail to eradicate carcinoma
cells that have entered the stem-state via activation of the epithelial-to-mesenchymal (EMT) program
with the consequent tumor relapse [9]. Since the mechanism through which EMT determines the
entrance into the stem state is still elusive [9], deep investigations of CSC induction through EMT
are crucial for the generation of new effective therapies that specifically target these cells. The ability
of cells that have exited the quiescent state to colonize secondary organs to form metastases and
to generate relapse is closely related to the mesenchymal-to-epithelial transition (MET) [9]. Indeed,
our data show that PDAC cells undergo EMT during CSC induction, and CSCs are able to undergo
MET, re-differentiate, increase their proliferation by exiting from quiescence, and become metabolically
active. These cells show a marked increase of lactate production in comparison to CSCs of origin and,
especially, to parental cells. Consistently, in vivo findings show that lactate accumulation within the
tumor correlates with poor clinical outcomes [49].
5. Conclusions
Since the eradication of CSCs remains a major challenge, our data have relevant implications in
cancer therapy. Indeed, the therapeutic targeting of specific metabolic CSC features will help to avoid
the pursuit of the quiescent state, which may represent the major culprit for cancer aggressiveness.
Furthermore, our data indicate that it is necessary to take into account that the steps of tumor and
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metastasis development pass through a metabolic plasticity of cancer cells that has to be further
characterized and validated in patients with different tumor types in order to develop the best strategy
for an effective cancer eradication. To accomplish this aim, a major attention will be given to the
identification of proteins that play a key role in the determination of EMT/MET and metabolic changes
in CSCs, in order to determine a possible causal link between these two events.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/7/1572/s1,
Figure S1: (A) Bright field images of Panc1 cells cultured in the SsM for 1, 4, and 7 days. Scale bar: 100 µm.
(B) Bright field images of PaCa44, PaCa3, and PC1J parental (P) cells and CSCs cultured for 8 weeks. Scale bar:
100 µm. C) Bright field representative images of Panc1 CSCs cultured in the stem-specific medium for 12 weeks.
Scale bar: 100 µm. Figure S2: Average of the sphere diameters (A) and representative images (B) of cells grown
for 30 days after the seeding of 1 cell/well of Panc1 P cells and CSCs. Scale bar: 100 µm. (C) Representative
images of soft agar colony formation assay of Panc1 P and CSCs. D) Beta-galactosidase-based assay for the
detection of senescent cells, which are indicated by arrows, in Panc1 positive control, P cells, and CSCs. Scale bar:
100 µm. Figure S3: Heatmap representation of the unsupervised hierarchical clustering of target gene expression
across all samples based on their ∆CT values obtained through real-time PCR. Figure S4: Metabolomic Pathway
Analysis (MetPA) generated by MetaboAnalyst software package by comparing (A) P cells versus CSCs 2 weeks;
(B) CSCs 2 weeks versus CSCs 4 weeks; (C) CSCs 4 weeks versus CSCs 8 weeks. All the matched pathways are
displayed as circles. The color of each circle is based on p-values (darker colors indicate more significant changes
of metabolites in the corresponding pathway), whereas the size of the circle corresponds to the pathway impact
score. Select pathways with high pathway impact and/or high p-value are labeled. Figure S5: qPCR analysis of
Glut-1 transporter, phosphofructokinase (PFK), and enolase in Panc1 P cells and CSCs. The values are reported as
fold change relative to P cells. Legend: white: parental (P) cells; light gray: CSCs 2 weeks; dark grey: CSCs 4
weeks; black: CSCs 8 weeks. Values are the means (± SE) of three independent biological replicates. Statistical
legend: p < 0.05 (*) P cells versus CSCs; (#) CSCs 4 weeks versus CSCs 8 weeks. Table S1: Analysis of mRNA
expression levels of stem markers (SOX2, NANOG, and OCT3/4) and of quiescence markers (MAD2L1, Cyclin B1,
and RPLP0) in the three PDAC cell lines PaCa44, PaCa3, and PC1J cultured in the SsM for 4 and 8 weeks.
Author Contributions: G.A., E.D.P., G.F., C.D.C., A.V., C.C., and J.B. conducted the experiments and acquired the
data. I.D., E.D.P., G.A., G.C., C.D.C., S.R., A.R., and D.C. designed the experiments and interpreted the results. I.D.,
E.D.P., G.A., and M.P. conceived and designed the various phases of the work. I.D. wrote the original draft of the
manuscript. M.P., M.T.S., A.R., S.R., C.A.C.-C., and D.C. wrote, reviewed and edited the manuscript. All authors
have read and agreed to the published version of the manuscript.
Funding: This work was supported by Joint Projects program 2017 from University of Verona to M.P. and by
Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR), Rome, Italy. A.R. was supported by a grant from
Associazione Italiana Ricerca Cancro (AIRC IG 2017/20749).
Acknowledgments: We thank Marcello Manfredi and Emilio Marengo (University of Eastern Piedmont,
Alessandria, Italy and ISALIT, Novara, Italy) for proteomic analysis by LC-MS/MS. We also thank Irene Sasso and
Giuliana Siragusa for helping with qPCR analysis. Thanks to “Centro Piattaforme Tecnologiche” of University of
Verona (Italy). We thank Gina Maria DeNicola for constructive criticisms of the manuscript.
Conflicts of Interest: The authors declare that they have no conflict of interests.
References
1. Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting cancer
incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United
States. Cancer Res. 2014, 74, 2913–2921. [CrossRef] [PubMed]
2. Abbruzzese, J.L.; Hess, K.R. New option for the initial management of metastatic pancreatic cancer? J. Clin.
Oncol. 2014, 32, 2405–2407. [CrossRef] [PubMed]
3. Neoptolemos, J.P.; Stocken, D.D.; Friess, H.; Bassi, C.; Dunn, J.A.; Hickey, H.; Beger, H.; Fernandez-Cruz, L.;
Dervenis, C.; Lacaine, F.; et al. A randomized trial of chemoradiotherapy and chemotherapy after resection
of pancreatic cancer. N. Engl. J. Med. 2004, 350, 1200–1210. [CrossRef] [PubMed]
4. Rasheed, Z.A.; Matsui, W. Biological and clinical relevance of stem cells in pancreatic adenocarcinoma.
J. Gastroenterol. Hepatol. 2012, 27 (Suppl. 2), 15–18. [CrossRef]
5. Bünger, S.; Barow, M.; Thorns, C.; Freitag-Wolf, S.; Danner, S.; Tiede, S.; Pries, R.; Görg, S.; Bruch, H.P.;
Roblick, U.J.; et al. Pancreatic carcinoma cell lines reflect frequency and variability of cancer stem cell markers
in clinical tissue. Eur. Surg. Res. 2012, 49, 88–98. [CrossRef]
Cells 2020, 9 22
6. Dalla Pozza, E.; Dando, I.; Biondani, G.; Brandi, J.; Costanzo, C.; Zoratti, E.; Fassan, M.; Boschi, F.; Melisi, D.;
Cecconi, D.; et al. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bidirectionally
convert into cancer stem cells. Int. J. Oncol. 2015, 46, 1099–1108. [CrossRef]
7. Sancho, P.; Alcala, S.; Usachov, V.; Hermann, P.C.; Sainz, B., Jr. The ever-changing landscape of pancreatic
cancer stem cells. Pancreatology 2016, 16, 489–496. [CrossRef]
8. Rhim, A.D.; Mirek, E.T.; Aiello, N.M.; Maitra, A.; Bailey, J.M.; McAllister, F.; Reichert, M.; Beatty, G.L.;
Rustgi, A.K.; Vonderheide, R.H.; et al. EMT and dissemination precede pancreatic tumor formation. Cell
2012, 148, 349–361. [CrossRef]
9. Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications.
Nat. Rev. Clin. Oncol. 2017, 14, 611–629. [CrossRef]
10. Phi, L.T.; Sari, I.N.; Yang, Y.G.; Lee, S.H.; Jun, N.; Kim, K.S.; Lee, Y.K.; Kwon, H.Y. Cancer Stem Cells (CSCs) in
Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018, 2018, 5416923.
[CrossRef]
11. Yang, Z.J.; Wechsler-Reya, R.J. Hit’em where they live: Targeting the cancer stem cell niche. Cancer Cell 2007,
11, 3–5. [CrossRef] [PubMed]
12. Di Carlo, C.; Brandi, J.; Cecconi, D. Pancreatic cancer stem cells: Perspectives on potential therapeutic
approaches of pancreatic ductal adenocarcinoma. World J. Stem Cells 2018, 10, 172–182. [CrossRef] [PubMed]
13. da Veiga Moreira, J.; Hamraz, M.; Abolhassani, M.; Schwartz, L.; Jolicoeur, M.; Peres, S. Metabolic therapies
inhibit tumor growth in vivo and in silico. Sci. Rep. 2019, 9, 3153. [CrossRef] [PubMed]
14. Viale, A.; Pettazzoni, P.; Lyssiotis, C.A.; Ying, H.; Sánchez, N.; Marchesini, M.; Carugo, A.; Green, T.; Seth, S.;
Giuliani, V.; et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Nature 2014, 514, 628–632. [CrossRef] [PubMed]
15. Dando, I.; Dalla Pozza, E.; Biondani, G.; Cordani, M.; Palmieri, M.; Donadelli, M. The metabolic landscape of
cancer stem cells. IUBMB Life 2015, 67, 687–693. [CrossRef]
16. Peiris-Pages, M.; Martinez-Outschoorn, U.E.; Pestell, R.G.; Sotgia, F.; Lisanti, M.P. Cancer stem cell metabolism.
Breast Cancer Res. 2016, 18, 55. [CrossRef]
17. Sancho, P.; Burgos-Ramos, E.; Tavera, A.; Kheir, T.B.; Jagust, P.; Schoenhals, M.; Barneda, D.; Sellers, K.;
Campos-Olivas, R.; Graña, O.; et al. MYC/PGC-1alpha Balance Determines the Metabolic Phenotype and
Plasticity of Pancreatic Cancer Stem Cells. Cell Metab. 2015, 22, 590–605. [CrossRef]
18. Dobbin, Z.C.; Landen, C.N. Isolation and characterization of potential cancer stem cells from solid human
tumors–potential applications. Curr. Protoc. Pharmacol. 2013, 63, 14–28. [CrossRef]
19. Franco, S.S.; Szczesna, K.; Iliou, M.S.; Al-Qahtani, M.; Mobasheri, A.; Kobolák, J.; Dinnyés, A. In vitro models
of cancer stem cells and clinical applications. BMC Cancer 2016, 16 (Suppl. 2), 738. [CrossRef]
20. Brandi, J.; Dando, I.; Dalla Pozza, E.; Biondani, G.; Jenkins, R.; Elliott, V.; Park, K.; Fanelli, G.; Zolla, L.;
Costello, E.; et al. Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis
and mevalonate pathways. J. Proteom. 2017, 150, 310–322. [CrossRef]
21. Lemma, S.; Avnet, S.; Salerno, M.; Chano, T.; Baldini, N. Identification and Validation of Housekeeping Genes
for Gene Expression Analysis of Cancer Stem Cells. PLoS ONE 2016, 11, e0149481. [CrossRef] [PubMed]
22. Brandi, J.; Di Carlo, C.; Manfredi, M.; Federici, F.; Bazaj, A.; Rizzi, E.; Cornaglia, G.; Manna, L.; Marengo, E.;
Cecconi, D. Investigating the Proteomic Profile of HT-29 Colon Cancer Cells After Lactobacillus kefiri SGL 13
Exposure Using the SWATH Method. J. Am. Soc. Mass Spectrom. 2019, 30, 1690–1699. [CrossRef]
23. Masgras, I.; Ciscato, F.; Brunati, A.M.; Tibaldi, E.; Indraccolo, S.; Curtarello, M.; Chiara, F.; Cannino, G.;
Papaleo, E.; Lambrughi, M.; et al. Absence of Neurofibromin Induces an Oncogenic Metabolic Switch
via Mitochondrial ERK-Mediated Phosphorylation of the Chaperone TRAP1. Cell Rep. 2017, 18, 659–672.
[CrossRef] [PubMed]
24. Lister, J.A.; Robertson, C.P.; Lepage, T.; Johnson, S.L.; Raible, D.W. nacre encodes a zebrafish microphthalmia-
related protein that regulates neural-crest-derived pigment cell fate. Development 1999, 126, 3757–3767.
[PubMed]
25. Rajendran, V.; Jain, M.V. In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells.
Methods Mol. Biol. 2018, 1692, 89–95.
26. Borowicz, S.; Van Scoyk, M.; Avasarala, S.; Rathinam, M.K.; Tauler, J.; Bikkavilli, R.K.; Winn, R.A. The soft
agar colony formation assay. J. Vis. Exp. 2014, e51998. [CrossRef]
Cells 2020, 9 23
27. Pang, M.F.; Georgoudaki, A.M.; Lambut, L.; Johansson, J.; Tabor, V.; Hagikura, K.; Jin, Y.; Jansson, M.;
Alexander, J.S.; Nelson, C.M.; et al. TGF-beta1-induced EMT promotes targeted migration of breast cancer
cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. Oncogene 2016,
35, 748–760. [CrossRef]
28. Hwang, K.L.; Goessling, W. Baiting for Cancer: Using the Zebrafish as a Model in Liver and Pancreatic
Cancer. Adv. Exp. Med. Biol. 2016, 916, 391–410.
29. Parasido, E.; Avetian, G.S.; Naeem, A.; Graham, G.; Pishvaian, M.; Glasgow, E.; Mudambi, S.; Lee, Y.;
Ihemelandu, C.; Choudhry, M.; et al. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in
Primary Pancreatic Ductal Carcinoma Cells. Mol. Cancer Res. 2019, 17, 1815–1827. [CrossRef]
30. Teng, Y.; Xie, X.; Walker, S.; White, D.T.; Mumm, J.S.; Cowell, J.K. Evaluating human cancer cell metastasis in
zebrafish. BMC Cancer 2013, 13, 453. [CrossRef]
31. Bao, B.; Ahmad, A.; Azmi, A.S.; Ali, S.; Sarkar, F.H. Overview of cancer stem cells (CSCs) and mechanisms of
their regulation: Implications for cancer therapy. Curr. Protoc. Pharmacol. 2013, 61, 14–25. [CrossRef] [PubMed]
32. Lonardo, E.; Cioffi, M.; Sancho, P.; Sanchez-Ripoll, Y.; Trabulo, S.M.; Dorado, J.; Balic, A.; Hidalgo, M.;
Heeschen, C. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS ONE
2013, 8, e76518. [CrossRef] [PubMed]
33. Mellor, H.R.; Ferguson, D.J.; Callaghan, R. A model of quiescent tumour microregions for evaluating
multicellular resistance to chemotherapeutic drugs. Br. J. Cancer 2005, 93, 302–309. [CrossRef] [PubMed]
34. Cho, I.J.; Lui, P.P.; Obajdin, J.; Riccio, F.; Stroukov, W.; Willis, T.L.; Spagnoli, F.; Watt, F.M. Mechanisms,
Hallmarks, and Implications of Stem Cell Quiescence. Stem Cell Rep. 2019, 12, 1190–1200. [CrossRef]
35. Calcinotto, A.; Kohli, J.; Zagato, E.; Pellegrini, L.; Demaria, M.; Alimonti, A. Cellular Senescence: Aging,
Cancer, and Injury. Physiol. Rev. 2019, 99, 1047–1078. [CrossRef]
36. Coller, H.A.; Sang, L.; Roberts, J.M. A new description of cellular quiescence. PLoS Biol. 2006, 4, e83. [CrossRef]
37. Moore, N.; Lyle, S. Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and
discussion of significance. J. Oncol. 2011, 2011, 396076. [CrossRef]
38. Marcon, B.H.; Holetz, F.B.; Eastman, G.; Origa-Alves, A.C.; Amorós, M.A.; de Aguiar, A.M.; Rebelatto, C.K.;
Brofman, P.R.; Sotelo-Silveira, J.; Dallagiovanna, B. Downregulation of the protein synthesis machinery is
a major regulatory event during early adipogenic differentiation of human adipose-derived stromal cells.
Stem Cell Res. 2017, 25, 191–201. [CrossRef]
39. Signer, R.A.; Magee, J.A.; Salic, A.; Morrison, S.J. Haematopoietic stem cells require a highly regulated
protein synthesis rate. Nature 2014, 509, 49–54. [CrossRef]
40. Chen, W.; Dong, J.; Haiech, J.; Kilhoffer, M.C.; Zeniou, M. Cancer Stem Cell Quiescence and Plasticity as
Major Challenges in Cancer Therapy. Stem Cells Int. 2016, 2016, 1740936. [CrossRef]
41. Wellen, K.E.; Hatzivassiliou, G.; Sachdeva, U.M.; Bui, T.V.; Cross, J.R.; Thompson, C.B. ATP-citrate lyase
links cellular metabolism to histone acetylation. Science 2009, 324, 1076–1080. [CrossRef] [PubMed]
42. Wong, C.C.; Qian, Y.; Yu, J. Interplay between epigenetics and metabolism in oncogenesis: Mechanisms and
therapeutic approaches. Oncogene 2017, 36, 3359–3374. [CrossRef] [PubMed]
43. Curtis, N.J.; Mooney, L.; Hopcroft, L.; Michopoulos, F.; Whalley, N.; Zhong, H.; Murray, C.; Logie, A.;
Revill, M.; Byth, K.F.; et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL,
NHL and Burkitt’s lymphoma anti-tumor activity. Oncotarget 2017, 8, 69219–69236. [CrossRef] [PubMed]
44. Pereira, S.; Kildegaard, H.F.; Andersen, M.R. Impact of CHO Metabolism on Cell Growth and Protein
Production: An Overview of Toxic and Inhibiting Metabolites and Nutrients. Biotechnol. J. 2018, 13, e1700499.
[CrossRef] [PubMed]
45. Shono, Y.; Kamouchi, M.; Kitazono, T.; Kuroda, J.; Nakamura, K.; Hagiwara, N.; Ooboshi, H.; Ibayashi, S.;
Iida, M. Change in intracellular pH causes the toxic Ca2+ entry via NCX1 in neuron- and glia-derived cells.
Cell Mol. Neurobiol. 2010, 30, 453–460. [CrossRef] [PubMed]
46. Ayob, A.Z.; Ramasamy, T.S. Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci. 2018, 25,
20. [CrossRef]
47. Valcourt, J.R.; Lemons, J.M.; Haley, E.M.; Kojima, M.; Demuren, O.O.; Coller, H.A. Staying alive: Metabolic
adaptations to quiescence. Cell Cycle. 2012, 11, 1680–1696. [CrossRef]
Cells 2020, 9 24
48. Yumoto, K.; Eber, M.R.; Berry, J.E.; Taichman, R.S.; Shiozawa, Y. Molecular pathways: Niches in metastatic
dormancy. Clin. Cancer Res. 2014, 20, 3384–3389. [CrossRef]
49. Kennedy, K.M.; Dewhirst, M.W. Tumor metabolism of lactate: The influence and therapeutic potential for
MCT and CD147 regulation. Future Oncol. 2010, 6, 127–148. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
